Research programme: metabolic disorders therapy - Advinus Therapeutics/Merck
Latest Information Update: 16 Jul 2016
At a glance
- Originator Advinus Therapeutics; Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus; Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in India
- 04 May 2009 Preclinical trials in Diabetes mellitus in India (unspecified route)